Algorithm for early detection of increased risk of colon cancer in non-adherent patients
CompanyRoche Deutschland Holding GmbH, Mannheim, Germany
Roche Deutschland Holding GmbH has developed the Colon Flag diagnostic algorithm for the early detection of the risk of colon cancer in (non-adherent) patients. All that is required for the examination is the values of a small blood count (MCH, hemoglobin, MCHC, RBC, haematocrit and MCV), as well as the patient's age and gender. The data is sent anonymously to the navify® Algorithm Suite. Within a cloud, the algorithm calculates an individual risk value for the patient with the support of big data sets, which is also compared with clinical reference data from the population. So far, it has been shown that Colon Flag is a highly effective diagnostic tool that is also able to identify “hidden signals” in the patient data and thereby reliably detect high-risk patients with a high level of sensitivity. The algorithm can be automatically integrated into existing IT systems, thereby enabling simple and user-friendly access from the laboratory. In summary, the method enables an early and precise risk assessment of the patient and thereby specifically supports doctors in clinical decision-making and the selection of a personalized treatment strategy.
ColonFlag™
www.roche.de
Added on: 02-08-2024
[1] https://diagnostics.roche.com/global/en/news-listing/2023/roche-introduces-navify--algorithm-suite--a-digital-library-of-m.html[2] https://www.roche.de/diagnostik/produkte-loesungen/digitale-loesungen/navify-colonflag
